Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Duncan v. Vical Incorporated et al
Case Number:
3:13-cv-02628
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
March 10, 2015
Biopharma Co. Didn't Lie About Cancer Drug Progress: Judge
A California federal judge on Monday dismissed a proposed shareholder class action accusing experimental drug developer Vical Inc. of misleading investors about its cancer drug, describing the complaint as an attempt to punish a corporation and its officers for expressing incorrect opinions.
-
October 31, 2013
Biopharma Co. Misled Investors On Cancer Drug Progress: Suit
Vical Inc., which researches and develops biopharmaceutical products for the prevention and treatment of serious diseases, on Wednesday was hit with a putative class action in California federal court by a shareholder who says the company made false statements about the progress of cancer drug Allovectin-7.